SCHEMBL4517094

SCHEMBL4517094

O=C1CCCN1C1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.40
HSD11B1 P28845 1/20 0.36
BRD4 O60885 1/20 0.35
BRD2 P25440 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NPY5R Q15761 3/20 0.35
MGLL Q99685 1/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
LTA4H P09960 1/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
KDM5A P29375 1/20 0.33
PIK3CD O00329 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28904129 0.88 DPP4 (0.36) JAK2HSD11B1NOS3NOS1NPY5R
SCHEMBL17185334 0.85
SCHEMBL6335314 0.83 NOS3 (0.45) BRD4BRD2NOS3NOS1NPY5R
SCHEMBL11842283 0.83 NOS3 (0.45) JAK2BRD4BRD2NOS3NOS1
SCHEMBL23917218 0.81 NOS3 (0.43) HSD11B1BRD4BRD2NOS3NOS1
SCHEMBL28282296 0.81 NOS3 (0.43) HSD11B1BRD4BRD2NOS3NOS1
SCHEMBL20858617 0.81 NOS3 (0.43) HSD11B1BRD4BRD2NOS3NOS1
SCHEMBL27939000 0.81 NOS3 (0.43) BRD4BRD2NOS3NOS1NPY5R
SCHEMBL22889 0.81 NOS3 (0.43) HSD11B1BRD4BRD2NOS3NOS1
SCHEMBL474722 0.80 NPY5R (0.40) BRD4BRD2NOS3NOS1NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270209-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. 2025-08-28 US disclosed
EP-3697410-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES Amgen Inc. (US) 2020-08-26 EP disclosed
WO-2019079578-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2019-04-25 WO disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
WO-2007124337-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 JAK2 4060/4885HSD11B1 1/4885BRD4 3776/4885
US-20250270209-A1 LRRK2 INHIBITORS LRRK2, PARK7, PINK1 JAK2 500/4885HSD11B1 3271/4885BRD4 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.